In metabolic diseases like obesity and type 2 diabetes, therapies aimed at enhancing lipid oxidation in mitochondria or reducing lipid accumulation in LDs could improve insulin sensitivity and glucose homeostasis. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.